THURSDAY, JUNE 25, 2015 8:30 am – Institute for Bioscience & Biotechnology Research (IBBR)
Manufacturing Science Analytics: Predictors of Biotherapeutic Product Quality
Industrial, federal, and academic researchers will gather to discuss the current trends in process modeling and its relation to the biotherapeutic “fingerprint.” On Thursday, June 25, 2015 at 8:30 am join the thought-leaders, policy-makers, and creators of biosimilars as we present current trends, ideas, and predictions.
Six months after the search began, 1776 is proud to announce that judges selected Twiga Fruits as the 2015 Challenge Cup Champion.
Twiga has created a market solution to solve the problem of rising food prices across Africa. Its solution offers farmers a formal guaranteed prices, handles the produce with care to eliminate loss and delivers directly to thousands of independent kiosks
Yet another report’s pointing out biotech’s bullish venture appeal – and how medical device investment continues to flag.
In fact, biotechnology funding for human therapeutics is so strong that its venture funding outpaces pharmaceuticals sevenfold, a PricewaterhouseCoopers venture analysis of the first quarter of 2015 life sciences sector found.
The U.S. congress has proposed budgets cuts for research, but more and more scientists are turning to crowdfunding to bring their projects to light.
On May 20, 2015, the US House Republicans voted to place limits on funding for scientific research. The bill, which passed 217 votes to 205, still has to through the Senate, but it sets an ominous tone for future research.
When this year’s winners of the InvestMaryland Challenge were announced, Bricata stood out.
Amid the Maryland companies who finished atop the Maryland Department of Business and Economic Development competition, the cybersecurity company was listed as hailing from Vienna, Va.
Osage University Partners, a Philadelphia-area venture firm that only invests in tech transfer spinouts, just closed its second fund – valued at $215 million.
About half of that funding will likely go towards life sciences companies – particularly in the therapeutics space, said managing partner William Harrington. Cancer, GI and cardiovascular drugs are the most interesting to Osage, he said, though the firm’s interested in diversifying its holdings. Most of the other investment will be made in tech companies.
The NIH has jumped onto the whole startup challenge-meets-accelerator trend – using it as a way to galvanize the private sector into licensing the government’s own technology.
It recently announced the winners of its Neuro Startup Challenge – a competition in which teams of students from various universities were tasked with with building out business plans around the NIH’s intellectual property. The teams worked to find ways to commercialize predetermined therapeutics, diagnostics and medical devices sanctioned by the government for startup use.
Baltimore entrepreneurs cleaned up at the Maryland Technology Development Corp.’s annual ICE Awards, which recognize some of TEDCO’s most successful portfolio companies.
Analytical Informatics, Lookingglass and Opiatalk CEO Tom Popomaronis, all based in Baltimore, took top honors for innovation, corporate excellence and entrepreneurship.
The statistics are staggering: 1 in 2 women and 1 in 3 men will be diagnosed with cancer in their lifetime. This means that cancer will very likely affect each and every one of us at some point in our lives — whether it is through our own personal diagnosis or through that of someone we love. In light of this, I’d like share eight things that we as survivors and potential targets of this disease need to know.
The region’s biggest venture capital raise of the year belongs to RegenxBio.
The Rockville-based biotech company has closed a $70.5 million Series D round led by new investor Vivo Capital, a Silicon Valley health care backer, and existing investors Venrock and Brookside Capital.
